معرفی
Sean Michael O'Brien serves as Associate Professor of Biostatistics & Bioinformatics at Duke University and is a member of the Duke Clinical Research Institute (DCRI). His academic home resides within the Department of Biostatistics & Bioinformatics, where he applies advanced statistical methodologies to cardiovascular research and healthcare systems analysis.
His educational foundation includes a Ph.D. from the University of North Carolina, Chapel Hill (2002) and a Research Fellowship at the National Institute of Environmental Health Sciences (NIEHS, 2002-2004).
Dr. O'Brien's research program centers on statistical methods for healthcare provider profiling, observational studies, and Bayesian data analysis, with deep specialization in cardiovascular clinical trials. He develops innovative approaches for analyzing complex healthcare data, particularly in coronary artery disease management and surgical outcomes. His methodological expertise bridges biostatistics with real-world clinical decision-making, focusing on risk modeling and comparative effectiveness research.
Analysis of his 10 most recent publications (2024-2025) reveals dominant themes in cardiovascular clinical trials, especially the landmark ISCHEMIA study investigating optimal management of chronic coronary disease. Key research trajectories include risk prediction modeling for cardiac surgery, comparative analysis of revascularization techniques, diagnostic test evaluation using imaging modalities, and sex-specific outcomes in cardiovascular interventions. The work consistently demonstrates application of Bayesian methods and observational study designs to large-scale clinical datasets.
Dr. O'Brien maintains an extensive grant portfolio supporting his research infrastructure and training initiatives:
- IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD) (2023-2030, NIH)
- Integrated Biostatistical Training for CVD Research (2022-2027, NC State University)
- RECOVER Infrastructure Modification 11 (Yr 3) (2022-2026, RTI International)
- ISCHEMIA-Extend_Resubmission (2022-2026, NYU)
- The North Carolina Congenital Heart Disease Surveillance Network (2019-2025, CDC)
- Postdoctoral Training in Cardiovascular Clinical Research (2003-2025, NIH)
- Duke CTSA (TL1) Year 5 (2018-2024, NIH)
- ACTIV-1 (2020-2023, Technical Resources International)
- ISCHEMIA-CKD SDCC (2013-2022, NIH)
- The ISCHEMIA Trial - SDCC (2011-2022, NIH)
His primary research affiliation is with the Duke Clinical Research Institute, a global leader in cardiovascular clinical trials and outcomes research that provides the collaborative environment for his methodological work. The DCRI connection facilitates direct application of his statistical innovations to major multicenter studies.
